Scolaris Content Display Scolaris Content Display

Transarterial (chemo)embolisation for liver metastases

This is not the most recent version

References

Additional references

ASERNIP‐S 2006

Australian Safety, Efficacy Register of New Interventional Procedures ‐ Surgical (ASERNIP‐S). Radiofrequency ablation of liver tumours (update): A systematic review. ASERNIP‐S Report No. 56. Adelaide, South Australia: ASERNIP‐S (http://www.surgeons.org/media/17297/RFAupdate.pdf) 2006 (accessed 27 September 2011).

Bangalore 2008

Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli FH. Peri‐operative beta‐blockers in patients undergoing non‐cardiac surgery. A meta‐analysis and trial sequential analysis of 12,306 patients from randomised trials. Lancet 2008;372:1962‐76.

Bilchik 2000

Bilchik AJ, Wood TF, Allegra D, Tsioulias GJ, Chung M, Rose DM, et al. Cryosurgical ablation and radiofrequency ablation for unresectable hepatic malignant neoplasms: A proposed algorithm. Archives of Surgery 2000;135(6):657‐64.

Bipat 2007

Bipat S, van Leeuwen MS, Ijzermans JN, Comans EF, Planting AS, Bossuyt PM, et al. Evidence‐based guideline on management of colorectal liver metastases in the Netherlands. Netherlands Journal of Medicine 2007;65(1):5‐14.

Breedis 1954

Breedis C, Young G. The blood supply of neoplasms in the liver. American Journal of Pathology 1954;30(5):969‐77.

Brok 2009

Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta‐analyses may be inconclusive ‐ trial sequential analysis adjustment for random error risk in conclusive neonatal meta‐analyses. International Journal of Epidemiology 2009;38:287‐98.

CTU 2011

Copenhagen Trial Unit. TSA ‐ Trial Sequential Analysis. http://ctu.dk/tsa/ Accessed 29 September 2011.

Decadt 2004

Decadt B, Siriwardena AK. Radiofrequency ablation of liver tumours: systematic review. Lancet Oncology 2004;5:550‐60.

DerSimonian 1986

DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88.

FDA 2011

U.S. Food, Drug Administration. FDA approvals and investigational device exemptions. http://www.fda.gov/ Accessed 29 September 2011.

Geoghegan 1999

Geoghegan J, Scheele J. Treatment of colorectal metastases. British Journal of Surgery 1999;86(2):145‐6.

Gluud 2008

Gluud LL, Thorlund K, Gluud C, Woods L, Harris R, Sterne JA. Correction: reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2008;149(3):219.

Gluud 2011

Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als‐Nielsen B, Colli A, et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2011, Issue 8. Art. No.: LIVER.

Greenland 1985

Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow‐up data. Biometrics 1985;41:55‐68.

Higgins 2011

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Colloboration, 2011. Available from www.cochrane‐handbook.org.

Hugh 1997

Hugh TS, Poston GJ. The aetiology and management of hepatic metastases. The Australian and New Zealand Journal of Surgery 1997;67(7):400‐9.

IARC 2008

International Agency for Research on Cancer. Cancer Incidence and Mortality Worldwide in 2008. http://globocan.iarc.fr/ (accessed 29 September 2011).

ICH‐GCP 1997

International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice1997 CFR & ICH Guidelines. Vol. 1, PA 19063‐2043, USA: Barnett International/PAREXEL, 1997.

Jaeger 1996

Jaeger HJ, Mehring UM, Castañeda F, Hasse F, Blumhardt G, Loehlein D, et al. Seguential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma. Cardiovascular and Interventional Radiology 1996;19(6):388‐96.

Jemal 2010

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 2010;60(5):277‐300.

Kjaergard 2001

Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135:982‐9.

Lau 2000

Lau WY. Primary liver tumors. Seminars in Surgical Oncology 2000;19(2):135‐44.

Llovet 2003

Llovet JM, Bruix J, for the Barcelona‐Clinic Liver Cancer Group. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429‐42.

Lopez 2006

Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence‐based management of hepatocellular carcinoma ‐ an updated analysis of randomized controlled trials. Alimentary Pharmacology & Therapeutics 2006;23(11):1535‐47.

Mantel 1959

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959;22:719‐48.

Markovic 1998

Markovic S, Gadzijev E, Stabuc B, Croce L, Masutti F, Surlan M. Treatment options in Western hepatocellular carcinoma: a prospective study of 224 patients. Journal of Hepatology 1998;29:650‐9.

McCarter 2000

McCarter MD, Fong Y. Metastatic liver tumours. Seminars in Surgical Oncology 2000;19(2):177‐88.

McLoughlin 2006

McLoughlin JM, Jensen EH, Malafa M. Resection of colorectal liver metastases: current perspectives. Cancer Control 2006;13(1):32‐41.

Michel 2002

Michel S, Sue B, Montpeyroux F, Hachemanne S, Blanc P, Domergue J. Liver resection or transplantation for hepatocellular carcinoma?. Journal of Hepatology 2002;26:1274‐80.

Moher 1998

Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet 1998;352:609‐13.

National Cancer Institute 2009

National Cancer Institute. SEER Cancer Statistics Review, 1975‐2007. http://seer.cancer.gov/csr/1975_2007/ (accessed 29 September 2011).

Oliveri 2011

Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2011, Issue 3. [DOI: 10.1002/14651858.CD004787.pub2]

Parkin 2002

Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. CA: A Cancer Journal for Clinicians 2005;55(2):74–108.

Parmar 1998

Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815‐34.

Royle 2003

Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591‐603.

Schulz 1995

Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273(5):408‐12.

Schwartz 2004

Schwartz JD, Beutler AS. Therapy for unresectable hepatocellular carcinoma: review of the randomized clinical trials‐II: systemic and local non‐embolization‐based therapies in unresectable and advanced hepatocellular carcinoma. Anti‐Cancer Drugs 2004;15:439‐52.

Sutherland 2006

Sutherland LM, Williams JAR, Padbury RTA, Gotley DC, Stokes B, Maddern GJ. Radiofrequency ablation of liver tumors. A systematic review. Archives of Surgery 2006;141:181‐90.

Thorlund 2009

Thorlund K, Devereaux PJ, Wetterslev J, Gyuatt G, Ioannidis JPA, Thabane L, et al. Can trial sequential monitoring boundaries reduce spurious inferences from meta‐analyses?. International Journal of Epidemiology 2009;38:276‐86.

Tierney 2007

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials 2007;8:16.

Vogl 2003

Vogl TJ, Mack MG, Balzer JO, Engelmann K, Straub R, Eichler K, et al. Liver metastases: neoadjuvant downsizing with transarterial chemoembolization before laser‐induced thermotherapy. Radiology 2003;229(2):457‐64.

Vogl 2007

Vogl TJ, Zangos S, Eichler K, Yakoub D, Nabil M. Colorectal liver metastases: regional chemotherapy via transarterial chemoembolization (TACE) and hepatic chemoperfusion ‐ an update. European Radiology 2007;17(4):1025‐34.

Vogl 2009

Vogl TJ, Gruber T, Balzer JO, Eichler K, Hammerstingl R, Zangos S. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology 2009;250(1):281‐9.

Weiss 1986

Weiss L, Grundmann E, Torhorst J. Hematogenous metastatic patterns in colonic carcinoma: an analysis of 1441 necropsies. Journal of Pathology 1986;140:195‐203.

Wetterslev 2008

Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta‐analysis. Journal of Clinical Epidemiology 2008;61(1):64‐75.

WHO 2011

World Health Organisation. International Clinical Trials Registry Platform (ICTRP). http://www.who.int/ictrp/en/ Accessed 29 September 2011.

Wood 1976

Wood C, Gillis C, Blumgart L. A retrospective study of patients with liver metastases from colorectal cancer. Clinical Oncology 1976;2:285‐8.

Wood 2008

Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.) 2008;336(7644):601‐5.